Pediatric Pharmacokinetic Study Quality Standard Needs Rethinking, Cmte. Tells FDA
Executive Summary
The Advisory Committee for Pharmaceutical Science and Clinical Pharmacology rejects FDA’s proposed standard, which the agency and sponsors have been operating under for six months, for deriving the sample size in pediatric PK trials. The agency’s approach does not offer enough flexibility and may not fit all pediatric PK study programs, committee members said.
You may also be interested in...
Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
‘Frontline’ Essential Workers, Persons 75 Years And Older Prioritized For Second Phase Of COVID Vaccination
Essential workers who cannot work remotely and have high levels of interaction with the public, and individuals ≥75 years old, should get vaccinated ahead of those 65-74 years old and those with comorbid conditions, CDC Advisory Committee on Immunization Practices recommends.
The Pfizer Effect: Moderna Tries To Escape Big Pharma’s Shadow At US FDA Vaccines Panel
Sponsor and agency sought to proactively address questions about the potential for anaphylactic reactions with the COVID-19 vaccine given the early real-world experience with Pfizer’s inoculation, which is also uses mRNA technology.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: